| Assessment Status |
Full HTA submission received from Applicant |
| HTA ID |
24041 |
| Drug |
Sotatercept |
| Brand |
Winrevair ® |
| Indication |
Sotatercept, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class II to III, to improve exercise capacity. |
| Rapid review commissioned |
09/09/2024 |
| Rapid review completed |
24/10/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of sotatercept compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/11/2024 |
| Pre-submission consultation with Applicant |
28/01/2025 |
| Full submission received from Applicant |
15/05/2025 |
